Advances in stem cell therapy for erectile dysfunction: preclinical evidence and emerging therapeutic approaches
Fu X. Sheikholeslami A. Zhanbyrbekuly U. Davoodi Asl F. Mussin N.M. Fazaeli H. Daniyalov K. Tanideh N. Mahdipour M. Kurmanalina M.A. Tamadon A.
2025Frontiers Media SA
Frontiers in Medicine
2025#12
The inability to get or sustain an erection strong enough for fulfilling sexual performance is the hallmark of the common disorder known as erectile dysfunction (ED). It mostly affects a significant percentage of men worldwide, particularly those aged 40 to 70. Even though phosphodiesterase type 5 inhibitors (PDEi) and other conventional therapies have demonstrated efficacy, they frequently prove insufficient for patients with underlying medical disorders such as diabetes, Peyronie’s disease, or post-prostatectomy. This review delves into the therapeutic capacity of stem cells for ED, emphasizing the latest clinical and preclinical studies that showcase their efficacy across various models. The review examines diverse sources of stem cells, including adipose-derived stem cells (ADSCs), bone marrow-derived stem cells (BMSCs), and other emerging sources such as urine-derived stem cells (UDSCs). Critical studies are highlighted, particularly those demonstrating the benefits of MSCs in ED models induced by cavernous nerve injury (CNI), diabetes, and other conditions. The review also explores the role of paracrine signaling, with a focus on factors like vascular endothelial growth factor (VEGF), and brain-derived neurotrophic factor (BDNF), which are involved in the regenerative process. Additionally, the capacity of stem cells with genetic modifications and the integration of stem cell therapy with adjunctive treatments such as platelet-rich plasma (PRP) and shock wave therapy are discussed. Overall, this review underscores significant progress in both clinical and preclinical studies on cell therapy for ED, paving the way for future clinical applications and innovative treatment strategies. Copyright
cardiovascular diseases , erectile dysfunction , mesenchymal stem cells , phosphodiesterase inhibitors , stem cell therapy
Text of the article Перейти на текст статьи
Department of Urology, Xianyang Central Hospital, Xianyang, China
Department of Mesenchymal Stem Cells, Academic Center for Education, Culture, and Research (ACECR), Qom, Iran
Department of Urology and Andrology, Astana Medical University, Astana, Kazakhstan
Department of General Surgery, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
Department of Pharmacology, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
PerciaVista R&D Co., Shiraz, Iran
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Department of Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
Department of Therapeutic and Prosthetic Dentistry, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
Department of Natural Sciences, West-Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
Department of Urology
Department of Mesenchymal Stem Cells
Department of Urology and Andrology
Department of General Surgery
Department of Pharmacology
Stem Cells Technology Research Center
PerciaVista R&D Co.
Stem Cell Research Center
Department of Applied Cell Sciences
Department of Therapeutic and Prosthetic Dentistry
Department of Natural Sciences
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026